A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC

NCT07334483 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

HCC

Interventions

DRUG: Yttrium [90Y] Microsphere Injection
OTHER: Conventional transcatheter arterial chemoembolization
DRUG: Camrelizumab
DRUG: Apatinib

Sponsor

GrandPharma (China) Co., Ltd.